<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03156647</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2016/GC-01bis</org_study_id>
    <nct_id>NCT03156647</nct_id>
  </id_info>
  <brief_title>Alpha-synuclein Level in Saliva to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome</brief_title>
  <acronym>PARKSYN</acronym>
  <official_title>Alpha-synuclein Level in the Saliva as a Potential Diagnostic Aid to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether a significant reduction in the total level of
      alpha-synuclein and significant increase in the oligomeric form of alpha-synuclein and
      therefore the ratio oligomeric:total alpha-synuclein occurs in patients with Parkinson
      disease compared to patients with drug-induced parkinsonian syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare saliva level of oligomeric alpha-synuclein between two groups of patients wth classical parkinsonian: patients with idiopathic Parkinson disease and patients with a acquired parkinsonian syndrome from anti-dopamine treatment.</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perform the first estimation of discriminatory capacity of saliva levels of oligomeric alpha-synuclein for diagnostic differentiation between idiopathic Parkinson disease and anti-dopamine induced acquired parkinsonian syndrome.</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare levels of total alpha-synuclein and the ratio of oligomeric alpha-synuclein:total alpha-synuclein between the two groups</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perform the first estimation of discriminatory capacity of saliva levels of total oligomeric alpha-synuclein and the ratio of oligomeric alpha-synuclein:total alpha-synuclein for diagnostic differentiation between two groups</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creation of a biobank with remaining samples</measure>
    <time_frame>Day 0</time_frame>
    <description>saliva samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS II-III-IV score</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UDysRs score</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>character of parkinsonian syndrome</measure>
    <time_frame>Day 0</time_frame>
    <description>symmetrical or asymmetrical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>akathisia</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire on non-motor symptoms in Parkinson disease</measure>
    <time_frame>Day 0</time_frame>
    <description>PD-NMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuro-psychological evaluation</measure>
    <time_frame>Day 0</time_frame>
    <description>BREF+MOCO score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GDS score</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interogation to determine extent of motor and non-motor clinical markers to differentiate the two groups</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Parkinsonian Disorders</condition>
  <arm_group>
    <arm_group_label>idiopathic Parkinson disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>iatrogenic parkinsonian syndrome</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Level of alpha-synuclein</intervention_name>
    <description>Test of levels of total and ratio total:oligomeric in saliva</description>
    <arm_group_label>idiopathic Parkinson disease</arm_group_label>
    <arm_group_label>iatrogenic parkinsonian syndrome</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from three centres:

        Patients hospitalized in the Quissac psychiatric unit Patients followed in the CHU Nimes
        neurological department for idiopathic Parkinson Patients followed in the CHU Montpellier
        neurological department
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be insured or the beneficiary of an insurance policy

          -  The patient is less than 55 years old

          -  For patients with acquired parkinsonian syndrome (UKPDSBB criteria) currently at HOEHN
             and YAHR stage ≤3:

               -  For patients recruited via a psychiatrist: after anti-dopamine treatment

               -  For patients recruited via a neurologist: having a recent diagnosis (≤2 years) of
                  Parkinson disease

        Exclusion Criteria:

          -  The subject is participating in another study

          -  The subject is in an exclusion period determined by a previous study

          -  The patients is under judicial protection

          -  The subject or their representative refused to sign the consent form

          -  It proves impossible to give the subject or their representative clear information.

          -  Patients with atypical degenerative parkinsonian syndrome

          -  Patients with vascular, post-traumatic, metabolic, toxic or genetic parkinsonian
             syndrome

          -  Appearance of parkinsonian syndrome prior to treatment with anti-dopamine

          -  Injection of botulinum toxin into the salivary glands

          -  Contra-indication on DAT-scan (unbalanced dysthyroidism, allergy, treatment with
             bupropion or amphetaminergics)

          -  Poor oral health (polyposis, gingivostomatitis) observed during the odontologist visit

          -  Patients not taking anti-psychotics with parkinsonian syndrome and normal DAT-scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Castelnovo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cécile Aerts, MD</last_name>
    <phone>06.62.04.48.11</phone>
    <email>cecileaerts34@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Gonzalez, MD</last_name>
      <phone>04 67 33 73 62</phone>
      <email>v-gonzalez@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Christian Geny, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahmoud Charif, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Lehmann, MD</last_name>
      <phone>04 67 33 71 24</phone>
      <email>s-lehmann@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain Lehmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Hirtz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Deville de Periere, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Castelnovo, MD</last_name>
      <phone>04.66.68.38.35</phone>
    </contact>
    <investigator>
      <last_name>Marie De Verdal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Collombier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Lapeyrie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

